Sale!

Crizocent

$800.00 $700.00

Crizocent(Crizotinib) i is indicated for the first-line treatment of adults with ALK-positive advanced NSCLC and for the treatment of adults with previously treated ALK-positive advanced NSCLC  & ROS1 (+) NSCLC. Crizotinib is an ALK and ROS1 (c-ros oncogene 1, receptor tyrosine kinase) inhibitor.

Crizocent (Crizotinib)

 

Product Description: Crizocent (Crizotinib) is a kinase inhibitor indicated for the treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) that is anaplastic lymphoma kinase (ALK)-positive or ROS 1 positive. Crizotinib is the first FDA-approved biomarker-driven therapy for both ALK positive and ROS1-positive metastatic NSCLC. It is the only FDA approved drug for ROS 1 positive NSCLC.

Indication: Crizocent(Crizotinib) i is indicated for the first-line treatment of adults with ALK-positive advanced NSCLC and for the treatment of adults with previously treated ALK-positive advanced NSCLC  & ROS1 (+) NSCLC. Crizotinib is an ALK and ROS1 (c-ros oncogene 1, receptor tyrosine kinase) inhibitor.

 

Manufacturer: Incepta Pharmaceuticals Ltd

Product Name : Crizocent
Generic Name : Crizotinib
Formulation : Capsule
Available size :60s
Strengths : 250mg

 

 

Manufacturer: Incepta Pharmaceuticals Ltd

Reviews

There are no reviews yet.

Only logged in customers who have purchased this product may leave a review.

You may also like…

  • Sale! Crizotinib (Crizonix) - Beacon Pharmaceuticals LimitedCrizonix

    Crizonix

    Anti cancer $800.00 $700.00
    Rated 0 out of 5